Entrada Therapeutics (TRDA) Fundamental Analysis: Revenue, Earnings & Valuation

7.24 / 10

Outperform

Fundamental analysis rates TRDA as Outperform with a 7.2/10 score. Strengths include high interest coverage, favorable PB‑ROE, strong inventory turnover, low debt ratios and solid asset‑MV. However, revenue growth is sharply negative year‑over‑year, dragging overall momentum.

Analysis Checks(7/10)

Revenue-MV

Value-3.89

Score1/3

Weight14.71%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value-87.94

Score1/3

Weight-1.16%

1M Return-0.38%

Inventory turnover ratio

Value103.94

Score2/3

Weight-3.38%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value34.32

Score3/3

Weight5.50%

1M Return1.67%

PB-ROE

Value-0.04

Score3/3

Weight37.31%

1M Return9.18%

Long-term debt to working capital ratio (%)

Value0.17

Score3/3

Weight2.59%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-3.43%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value-87.94

Score1/3

Weight-0.91%

1M Return-0.30%

Cost of sales ratio (%)

Value64.41

Score2/3

Weight-3.25%

1M Return-1.13%

Asset-MV

Value-0.55

Score3/3

Weight52.01%

1M Return11.61%

Is TRDA fundamentally strong?

TRDA scores 7.24/10 on fundamentals and holds a Discounted valuation at present. Backed by its -39.13% ROE, -565.48% net margin, -3.59 P/E ratio, 1.69 P/B ratio, and -297.16% earnings growth, these metrics solidify its Outperform investment rating.